AYTU BIOPHARMA, INC (AYTU) research

AYTU BIOPHARMA, INC
ShareXLinkedInReddit
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Last price
$2.23
As of

AYTU BIOPHARMA, INC (AYTU): 3 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-22.

As of . Source: SEC EDGAR filings for AYTU. Method and limitations.

SHARE THIS CARD

Share the AYTU intelligence card

A branded snapshot of AYTU: the smart money composite, cross family confluence, and the top current signal, with a link back to this page. Post it, download it, or embed it anywhere.

Kresmion AYTU intelligence card preview
Post to X
LIVE TERMINAL

See AYTU live in the terminal

Track AYTU's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.

Open the live AYTU terminal, free

Active signals for AYTU

FREE, NO ACCOUNT

Every signal on AYTU, as it fires

You are seeing 5 of 7 signals recorded on AYTU since 2026-05-16.

The five above landed across 4 days. The other 2 were recorded on those same days.

Get it by email

No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.

Join on Telegram
Join on Telegram

One tap. Live alerts, no email needed.

Largest reported share positions in AYTU (2026Q2)

Manager / securityMarket value% portfolioQoQ
TWO SIGMA INVESTMENTS, LPCUSIP 054754858 · 2026Q2$226K0.00%,
RENAISSANCE TECHNOLOGIES LLCCUSIP 054754858 · 2026Q2$225K0.00%,
CITADEL ADVISORS LLCCUSIP 054754858 · 2026Q2$106K0.00%,

Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.

Recent SEC filings, AYTU

AYTU against its peers

AYTU's operating margin of -14.4% ranks in the 46th percentile of 11 Drug Manufacturers - Specialty & Generic sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-06-30.

MetricAYTUPeer medianPercentilen
Revenue FY57.6M USD26.6M USD7014
Revenue YoY-13.3%n/an/a3
Gross margin64.0%45.6%7911
Operating margin-14.4%-10.7%4611
Net margin-24.8%-18.8%4613
Return on equity-40.4%-17.4%2911

Peers (15): BFRI, TXMD, ETST, ITHUF, RAPH, CXXIF, INIS, MRMD, RMTI, CPHI, HYEX, CABR, PLNH, BIOE, SCYX. Left out: MCUJF (period gap), UPC (period gap), ROMJF (no annual filing), CPIVF (no annual filing), OPTH (no annual filing), HSTI (period gap), TRUFF (no annual filing), CNTMF (no annual filing), IXHL (no annual filing), GSTK (no annual filing). Fiscal periods ending between 2025-12-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (AYTU: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.

Related tickers

See more AYTU signals as they fire

Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to AYTUand get the insider, 13F, options, and confluence read in one view.

Open the live AYTU terminal, free